Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex
References (25)
- et al.
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity
Biochem Pharmacol
(1987) - et al.
Drug-induced pancreatitis: a critical review
Gastroenterology
(1980) - et al.
Hypertriglyceridemia in the acquired immunodeficiency syndrome
Am J Med
(1989) - et al.
Association of painful peripheral neuropathy in AIDS with cytomegalovirus infection
Lancet
(1989) - et al.
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy virus-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides
Proc Natl Acad Sci USA
(1986) - et al.
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro
Proc Natl Acad Sci USA
(1987) - et al.
Myelotoxicity of new anti-HIV drugs (2',3'-dideoxynucleosides) on human hematopoietic progenitor cells in vitro
Exp Hematol
(1989) - et al.
Bone marrow toxicity of dideoxyinosine
N Engl J Med
(1989) - et al.
Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine
J Exp Med
(1989) - et al.
Cellular pharmacology of the anti-HIV agent 2',3'-dideoxyadenosine
(1988)
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine
Science
(1989)
The National Cancer Institute phase I study of ddI administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles
Rev Infect Dis
(1990)
Cited by (226)
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
2010, Antiviral ResearchPeripheral neuropathy in HIV infection
2007, Handbook of Clinical NeurologyCitation Excerpt :TN is associated with neurotoxic adverse effects of the dideoxynucleoside analogues of reverse transcriptase inhibitors (ddN). Early clinical trials showed that the effects of specific ddN, including didanosine (ddI), stavudine (d4T) and zalcitabine (ddC), are dose‐dependent (Simpson and Tagliati, 1995), and may trigger, aggravate or unmask painful DSP (Yarchoan et al., 1990). ddC is more potent than ddI, which is more potent than d4T in causing sensory neurotoxicity.
Didanosine
2017, Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh EditionToolbox: Neuropsychiatric adverse effects of antimicrobial agents
2013, Mental Health Clinician
Copyright © 1990 Published by Elsevier Ltd.